

THE ROLE OF GENETIC TESTING IN EARLY DETECTION OF ONCOLOGICAL DISEASES

Sheraliyev Ilyosjon Ibroxim o'g'li

Assistant of the Department of Pathological

Anatomy of the Tashkent Medical Academy

Abstract

This article examines the role of genetic testing in the early detection of oncological diseases. Genetic diagnostic tools, particularly molecular analyses, are evaluated as important instruments for identifying individual characteristics of cancer, assessing risk factors, and developing personalized prevention and treatment strategies. The article analyzes the effectiveness and prospects of genetic testing based on contemporary scientific research.

Keywords: Genetic testing, oncological diseases, early diagnosis, BRCA1, molecular diagnostics, PCR, personalized medicine.

Introduction:

Oncological diseases are currently considered one of the most serious problems facing the global healthcare system. The complexity of these diseases, their detection in late stages, and high mortality rates make the issue of their early detection urgent. Early detection of oncological processes increases treatment effectiveness and significantly improves patients' quality of life. In this regard, genetic testing is widely used in medical practice as an important tool.

Literature Review:

Shigakova and Ivanova's research on medical genetics emphasizes the importance of genetic testing in early detection of oncological diseases. Bobumurodov's work demonstrates mutations in genes such as BRCA1, BRCA2, and TP53 as major factors in cancer development. The fundamental research conducted by the Cancer Genome Atlas Research Network provides molecular classification of colorectal cancer and highlights targeted therapy opportunities based on this classification. Stephens and colleagues' research on breast cancer genome reveals the role of genetic recombinations in early diagnosis. Kalmikova and others' manual on PCR technology practically substantiates modern techniques for detecting genetic mutations.

Lyutsiya Anvarovna Shigakova and Lada Yevgenyevna Ivanova's research titled "Current Issues of Medical Genetics in the 21st Century" extensively analyzes the role of genetic diagnostics in modern medicine. The authors pay special attention to the role of genetic testing not only in identifying hereditary diseases but also in early detection of oncological diseases. According to them, molecular genetic analysis tools can identify individual characteristics of cancer and develop personalized prevention and treatment approaches.[1] The theoretical foundations and practical examples presented in the research substantiate the necessity of

genetic monitoring systems for accurately determining oncological risk factors. The authors also emphasize that early disease detection can reduce the economic burden on the healthcare system and improve patients' quality of life. These scientific perspectives highlight the importance of genetic testing in oncological screening and formation of individual therapy regimens, confirming the relevance of scientific approaches in this direction.

M. Bobumurodov's scientific article "Gene Mutations and Their Pathology" provides an in-depth analysis of genetic mutations and their pathogenic role in the development of various diseases, particularly oncological processes. The author emphasizes that genetic changes in the organism can be considered as the main cause of many oncological diseases. The research shows mutations in BRCA1, BRCA2, TP53, and other tumor-related genes as major factors increasing susceptibility to cancer diseases.[2] According to Bobumurodov's views, detecting such mutations through genetic testing enables early diagnosis, which in turn plays an important role in developing individual treatment strategies. The article emphasizes that identifying hereditary factors through genetic testing allows for establishing cancer prevention measures even for healthy individuals. This approach further strengthens the role of genetic diagnostics in implementing comprehensive medical measures aimed at assessing and reducing oncological risk. The author's analyses complement contemporary scientific approaches to the topic and confirm the relevance of genetic testing in early diagnosis in oncology.

The fundamental research "Comprehensive Molecular Characterization of Human Colon and Rectal Cancer" published by the Cancer Genome Atlas Research Network extensively studies the molecular characteristics of intestinal cancer. This work provides detailed analysis of genetic mutations, epigenetic changes, and gene expression characteristics associated with colorectal cancer. The research authors have shown that based on genetic profiling, these types of cancers can be divided into several biological groups, which serves as a basis for developing individual approaches and targeted therapy. Through molecular classification, the main stages of cancer development and key factors affecting treatment prognosis have been identified.[3] Particularly, the identification of biomarkers such as microsatellite instability and mutations in KRAS, BRAF, and PIK3CA genes increases the importance of genetic testing. The research results enable early detection of colorectal cancer through genetic testing and determination of optimal treatment directions for patients. The diagnostic and treatment strategies developed based on these molecular analyses further strengthen the prospects of genetic approaches in the fight against oncological diseases. This scientific source provides relevant scientific foundations for the topic and creates an opportunity for deeper understanding of the role of genetic testing in early diagnosis.

The research "Complex Landscapes of Somatic Rearrangement in Human Breast Cancer Genomes" prepared by Stephens P.J., McBride D.J., Lin M-L, and colleagues extensively analyzes somatic rearrangements occurring in breast cancer genomes. The authors used advanced sequencing technologies to identify the nature of complex genetic changes occurring in breast tumors. The research results show that breast cancer genomes have undergone extensive chromosomal changes, disrupted the mutual arrangement of genes and served the process of oncogene transformation.[4] These genetic recombinations provide the opportunity

to identify many new biomarkers and use them for diagnostic purposes. Based on the genetic anomalies identified in the research, the importance of developing genetic tests for early detection of oncological diseases is substantiated. This analytical approach creates the opportunity to identify high-risk patients through genetic screening and implement targeted preventive measures for them. The results further deepen the diagnostic and therapeutic importance of genetic testing, making them an integral part of early detection strategies in oncology. This research demonstrates contemporary achievements in molecular oncology within the scope of the topic and expands the possibilities of applying genetic analyses in clinical practice.

The manual "Fundamentals of Polymerase Chain Reaction with Different Detection Formats" prepared by Kalmikova M.S., Kalmikov M.V., and Belousova R. thoroughly covers the theoretical and practical aspects of polymerase chain reaction technology. The authors extensively analyze the possibilities of applying this technology in genetic research, particularly for diagnostic purposes. The work explains methods for detecting genetic material through various detection formats, and this approach is considered one of the main tools in early detection of oncological diseases. It is emphasized that changes, mutations, and genetic markers in DNA can be accurately identified using PCR technology. Particularly, PCR-based tests for detecting mutations in genes such as BRCA1 and BRCA2 have high sensitivity and are of great importance in identifying individuals at cancer risk and developing individual preventive measures.[5] The technical information and methodological approaches presented in this work create a scientific basis for understanding the effectiveness of genetic testing in early diagnosis in oncology. As a result, PCR technology is considered a universal tool widely used in medical genetics and confirms genetic analyses as a reliable method for early detection of oncological diseases.

Research Methodology:

The methodological approach used in the article is aimed at analyzing literary sources, generalizing scientific evidence based on existing genetic research, and examining the possibilities of early cancer detection based on molecular diagnostic technologies (such as PCR). The research focuses on assessing cancer risk through advanced sequencing technologies and molecular biomarkers. Genetic testing enables risk assessment by detecting changes in DNA, RNA, and other molecular structures in the organism. Through such tests, it becomes possible to determine the probability of oncological diseases arising under the influence of hereditary factors. Particularly, mutations in BRCA1 and BRCA2 genes have been scientifically proven to be directly related to the risk of developing breast and ovarian cancer. Additionally, these types of tests are also effective tools for detecting other hereditary oncological syndromes, such as Lynch syndrome or Li-Fraumeni syndrome. Genetic examinations are not limited to identifying risk factors. They also help in developing individual preventive measures and determining treatment strategies. For example, prophylactic surgical procedures, dietary regimens, regular screening, and other individual approaches may be

recommended for patients at high risk. This provides the opportunity to detect the disease before its onset or prevent it.

Analysis and Results:

Analyses show that mutations present in the organism are identified through genetic testing, and individual oncological risk levels are assessed. Particularly, changes in genes such as BRCA1/2, KRAS, and BRAF are detected with high sensitivity, and individual prevention plans can be developed for patients. Based on the Cancer Genome Atlas, cancer types are molecularly classified, creating a foundation for developing optimal treatment strategies. PCR technology significantly accelerates the diagnostic process and enables early diagnosis. Additionally, genetic testing can identify the type of oncological disease, cellular mutations, and medications sensitive to these changes. This pharmacogenetic approach has become an integral part of personalized medicine in contemporary oncology. Targeted therapy selected based on genetic testing can significantly improve patient clinical outcomes. This approach is particularly important in improving treatment effectiveness in advanced diseases.

In some cases, genetic testing provides more accurate information about disease recurrence risk, metastasis tendency, and treatment prognosis. For example, in colorectal cancer cases, if mutations in KRAS and NRAS genes are detected, this becomes an important factor in treatment selection. Based on such information, therapeutic approaches are optimized, resulting in more effective treatment processes.

Discussion:

Early diagnosis in oncology plays a decisive role in improving treatment effectiveness and quality of life. The implementation of genetic testing provides the opportunity to identify genetic factors leading to cancer in advance, creating possibilities for taking preventive measures for individuals at risk. However, the widespread application of tests also requires addressing issues such as the need for technical and economic resources, as well as ensuring the confidentiality of genetic information. Individuals at familial oncological risk are identified through genetic testing. Through this approach, early preventive measures are taken for individuals who have not yet manifested the disease. This includes implementing individual screening regimens, recommendations for adopting a healthy lifestyle, and regular monitoring. These preventive measures serve to reduce the overall prevalence of oncological diseases.

One of the important aspects related to the implementation of genetic examinations is ethical and social issues. The confidentiality of patients' genetic information, the possibility of its misinterpretation, or causing social discrimination are among the urgent issues. Therefore, genetic testing should only be performed by qualified specialists, and results should be explained to patients along with psychological counseling. The widespread application of genetic testing in medical practice has fundamentally changed approaches to fighting diseases. These tests enable doctors to select individual treatment strategies based on the patient's genetic profile. Particularly in oncology, this approach is an important factor in controlling the disease, shortening treatment periods, and preventing relapses.

The implementation of genetic testing is important not only for patients but also for healthy citizens. By identifying hereditary factors, the risk of oncological disease development is assessed for healthy individuals. As a result, these individuals take measures to reduce risk factors by changing their lifestyle, eating healthily, abandoning harmful habits, and undergoing regular medical examinations. Currently, many major oncological centers and scientific laboratories worldwide are conducting research to develop new genetic tests. Some of them are aimed at increasing sensitivity levels in detecting early stages of disease, while others are comprehensive tests capable of detecting more mutations. Additionally, active work is being conducted on technologies to improve the reliability and accuracy of test results and analyze them rapidly.

Conclusion:

Genetic testing is recognized as a contemporary tool providing high sensitivity and accurate results in early detection of oncological diseases. The research presented in the article deeply reveals the role and prospects of genetic diagnostics in oncology. The concept of personalized medicine can be implemented through scientifically based molecular approaches. The widespread implementation of genetic testing in medical practice serves as an important step in fighting oncological diseases. They serve as important tools in identifying disease risk, determining individual preventive measures, selecting treatment tactics, and assessing disease prognosis. In the future, with the development of medical genetics, the effectiveness and application areas of genetic testing will expand further. This opens the door to new opportunities in fighting oncological diseases.

References:

1. Шигакова, Люция Анваровна, and Лада Евгеньевна Иванова. "Актуальные вопросы медицинской генетики XXI века." 2022. – С 98.
2. Бобумуродова, Муборак Миркомилловна. "Генные мутации и их патология." 2023. – С. 180-184.
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, 2012. - 12-13p.
4. Stephens P.J, McBride D.J., Lin M-L. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes // *Nature*. - 2009. - Vol. 462. - P.1005-1010.
5. Калмыкова М.С., Калмыков М.В., Белоусова Р. Основы полимеразной цепной реакции с разными форматами детекции: Учебное пособие. - Спб.: Издательство «Лань», 2009. - 80 с